Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 5 | Mind Blowing Facts

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

MarketBeat

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Barchart

This Moderna leader uses AI to resolve conflict on the executive team—all before it even happens

“I think I’m pretty good with people, but it gives me an advantage that I didn’t have before.”

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayed

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.

LiveScience

Moderna Stock: Analyst Estimates & Ratings

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Moderna study shows immune response in older adults for a combo flu and COVID-19 shot

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a company-funded study

The Independent UK

From COVID to cancer: Why Canada’s RNA vaccine leadership matters more than ever

As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax

The Independent UK

Moderna Faces Suspension After Offering UK Children £1,500 And Teddy Bears To Join COVID Trials

Moderna, known for its COVID-19 vaccines, has been found guilty of 10 breaches of regulatory code after it marketed its booster jab trials towards children.

International Business Times UK

Novavax says its COVID-19 shot is on track for full FDA approval after delay

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the Food and Drug Administration

The Independent UK

What to Expect From Moderna's Q1 2025 Earnings Report

Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Barchart

What are mRNA vaccines, and how do they work?

mRNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there.

LiveScience

Analysts at Trump ally Howard Lutnick’s former firm call RFK Jr. ‘an anti-vax, conspiracy theorist with inadequate training’

RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.

Fortune

Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says 'wishes subservient confirmation of his misinformation and lies'

Massive cuts to personnel and funding within the Department of Health and Human Services presents a headache for vaccine approval and development, analysts say.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

Trump administration at ‘war’ with mRNA technology: scientists alarmed vaccine skeptics could kill research

Public health experts are sounding the alarm over recent move by the NIH to collect information about funding for research into mRNA technology

Barchart

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

Reason

Are COVID-19 Vaccines Safe and Effective?

Five years after Donald Trump declared a national COVID-19 emergency, here's what the research says.

MarketBeat

Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now?

A promising pipeline provides long-term potential for Moderna.

MarketBeat

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

Barchart

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

The Guardian - UK

What has the UK Covid inquiry learned so far about vaccines and treatments?

In fourth part of the inquiry, questons were asked about vaccine trials, procurement and the UK’s preparedness for future pandemics

Barchart

Here's What to Expect From Moderna's Next Earnings Report

Moderna is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit dip.

Fortune

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.

MarketBeat

After a Reset Year, Is Moderna Stock Poised for a Comeback?

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Health and Human Services

278 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.